Hyperhomocysteinemia potentiates hyperglycemia-induced inflammatory monocyte differentiation and atherosclerosis

Diabetes

Volumn 63, Issue 12, 2014, Pages 4275-4290

  Fang, Pu ^a   Zhang, Daqing ^a   Cheng, Zhongjian ^a   Yan, Chenghui ^b   Jiang, Xiaohua ^a   Kruger, Warren D ^c   Meng, Shu ^a   Arning, Erland ^d   Bottiglieri, Teodoro ^d   Choi, Eric T ^a   Han, Yaling ^b   Yang, Xiao Feng ^a   Wang, Hong ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Shenyang Northern Hospital   (China)

^c FOX CHASE CANCER CENTER   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CYSTATHIONINE BETA SYNTHASE; DNA METHYLTRANSFERASE 1; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; STREPTOZOCIN; TRIACYLGLYCEROL; ZINC ION;

AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; BLOOD; BONE MARROW; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; INFLAMMATORY CELL; LIPID BLOOD LEVEL; LIPID DIET; MACROPHAGE; MONOCYTE; MONONUCLEAR CELL; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; SPLEEN; SPLEEN CELL; ADVERSE EFFECTS; ANIMAL; ATHEROSCLEROSIS; COMPLICATION; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CYSTATHIONINE BETA-SYNTHASE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; HUMANS; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; INFLAMMATION; MACROPHAGES; MICE; MICE, TRANSGENIC; MONOCYTES;

EID: 84911890998     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0809     Document Type: Article

References (50)

1. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-291
2. Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003;108:933-938
3. Smulders YM, Rakic M, Slaats EH, et al. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999;22:125-132
4. Hofmann MA, Kohl B, Zumbach MS, et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21:841-848
5. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998;18:133-138
6. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 2004;140:94-100
7. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation 2000;101:1506-1511
8. Okada E, Oida K, Tada H, et al. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 1999;22:484-490
9. Brazionis L, Rowley K Sr, Itsiopoulos C, Harper CA, O'Dea K. Homocysteine and diabetic retinopathy. Diabetes Care 2008;31:50-56
10. Hoogeveen EK, Kostense PJ, Eysink PE, et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med 2000;160:2984-2990
11. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000;23:1816-1822
12. Vaccaro O, Ingrosso D, Rivellese A, Greco G, Riccardi G. Moderate hyperhomocysteinaemia and retinopathy in insulin-dependent diabetes. Lancet 1997;349:1102-1103
13. Neugebauer S, Baba T, Kurokawa K, Watanabe T. Defective homocysteine metabolism as a risk factor for diabetic retinopathy. Lancet 1997;349:473-474
14. House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010;303:1603-1609DOI: 10.1001/jama.2010.490
15. Ray JG, Kearon C, Yi Q, et al.; Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med 2007;146:761-767
16. Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE. Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes 2009;58:1921-1928
17. Wiltshire EJ, Gent R, Hirte C, Pena A, Thomas DW, Couper JJ. Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. Diabetes 2002;51:2282-2286
18. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013;339:286-291
19. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013;19:859-868
20. Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 2012;28:137-161
21. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013;339:172-177
22. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013;38:1092-1104
23. Taniguchi A, Fukushima M, Nakai Y, et al. Soluble tumor necrosis factor receptor 1 is strongly and independently associated with serum homocysteine in nonobese Japanese type 2 diabetic patients. Diabetes Care 2006;29:949-950
24. Aso Y, Okumura K, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care 2003;26:2622-2627
25. Targher G, Zenari L, Bertolini L, Falezza G, Muggeo M, Zoppini G. Plasma total homocysteine levels are associated with von Willebrand factor, soluble intercellular adhesion molecule-1, and soluble tumor necrosis factor-alpha receptors in young type 1 diabetic patients without clinical evidence of macrovascular complications. Diabetes Care 2001;24:1496-1497
26. Zhang D, Jiang X, Fang P, et al. Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice. Circulation 2009;120:1893-1902
27. Zhang D, Fang P, Jiang X, et al. Severe hyperhomocysteinemia promotes bone marrow-derived and resident infl ammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice. Circ Res 2012;111:37-49
28. Wang L, Jhee KH, Hua X, DiBello PM, Jacobsen DW, Kruger WD. Modulation of cystathionine beta-synthase level regulates total serum homocysteine in mice. Circ Res 2004;94:1318-1324
29. Watanabe M, Osada J, Aratani Y, et al. Mice deficient in cystathionine betasynthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci U S A 1995;92:1585-1589
30. Ducros V, Belva-Besnet H, Casetta B, Favier A. A robust liquid chromatography tandem mass spectrometry method for total plasma homocysteine determination in clinical practice. Clin Chem Lab Med 2006;44:987-990
31. Inoue-Choi M, Nelson HH, Robien K, et al. One-carbon metabolism nutrient status and plasma S-adenosylmethionine concentrations in middle-aged and older Chinese in Singapore. Int J Mol Epidemiol Genet 2012;3:160-173
32. Jamaluddin MD, Chen I, Yang F, et al. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood 2007;110:3648-3655
33. Zimny J, Sikora M, Guranowski A, Jakubowski H. Protective mechanisms against homocysteine toxicity: the role of bleomycin hydrolase. J Biol Chem 2006;281:22485-22492
34. Goldberg MD, Lo RC, Abele S, Macka M, Gomez FA. Development of microfluidic chips for heterogeneous receptor-ligand interaction studies. Anal Chem 2009;81:5095-5098
35. Walsh JG, Muruve DA, Power C. Inflammasomes in the CNS. Nat Rev Neurosci 2014;15:84-97
36. Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010;33:156-161
37. Meigs JB, Jacques PF, Selhub J, et al.; Framingham Offspring Study. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 2001;24:1403-1410
38. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004;140:9-17
39. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care 1991;14:839-855
40. Kang X, Zhong W, Liu J, et al. Zinc supplementation reverses alcoholinduced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. Hepatology 2009;50:1241-1250
41. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007;117:195-205
42. Stabler SP, Steegborn C, Wahl MC, et al. Elevated plasma total homocysteine in severe methionine adenosyltransferase I/III deficiency. Metabolism 2002;51:981-988
43. Ingrosso D, Cimmino A, Perna AF, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003;361:1693-1699
44. Linhart HG, Troen A, Bell GW, et al. Folate deficiency induces genomic uracil misincorporation and hypomethylation but does not increase DNA point mutations. Gastroenterology 2009;136:227-235.e3
45. James SJ, Melnyk S, Pogribna M, Pogribny IP, Caudill MA. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002;132(Suppl.):2361S-2366S
46. Jamaluddin MS, Yang X, Wang H. Hyperhomocysteinemia, DNA methylation and vascular disease. Clin Chem Lab Med 2007;45:1660-1666
47. Mackay DJ, Callaway JL, Marks SM, et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat Genet 2008;40:949-951
48. Boonen SE, Mackay DJ, Hahnemann JM, et al. Transient neonatal diabetes, ZFP57, and hypomethylation of multiple imprinted loci: a detailed follow-up. Diabetes Care 2013;36:505-512
49. Toperoff G, Aran D, Kark JD, et al. Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet 2012;21:371-383
50. Olsen AS, Sarras MP Jr, Leontovich A, Intine RV. Heritable transmission of diabetic metabolic memory in zebrafish correlates with DNA hypomethylation and aberrant gene expression. Diabetes 2012;61:485-491